LENZ Announces FDA Approval of VIZZ for Presbyopia

On July 31, 2025, LENZ Therapeutics announced that the U.S. Food and Drug Administration (FDA) approved VIZZ (aceclidine ophthalmic solution) 1.44 percent, making it a landmark approval for the treatment of presbyopia—a condition affecting approximately 128 million adults in the U.S. VIZZ is the first aceclidine-based eye drop approved to enhance near vision in adults with this condition. The company expects to have samples available in the U.S. as early as October 2025, with a full commercial rollout by mid-Q4 2025. Wilson Sonsini Goodrich & Rosati, serving as outside general counsel, advised LENZ on corporate and intellectual property matters concerning the FDA’s decision. The approval of aceclidine as a new chemical entity in the U.S. marks a global first for presbyopia treatment. The team advising LENZ included Dan Koeppen, Ben Capps, Mike Hostetler, and Ian Edvalson.